Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 13/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 13/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 13/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 13/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 12/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 12/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 11/20 | 1.00 |
| ▸ | GRIK3 | Q13003 | 11/20 | 1.00 |
| ▸ | GRIK4 | Q16099 | 6/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7662246 | 0.92 | GRIA1 (0.86) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7666995 | 0.88 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8681277 | 0.87 | GRIA1 (0.76) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8672098 | 0.87 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8611517 | 0.86 | GRIK1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7668356 | 0.85 | GRIA1 (0.75) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7662232 | 0.85 | GRIA1 (0.87) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7662239 | 0.84 | GRIA1 (0.72) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7664438 | 0.83 | GRIK1 (0.77) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7476602 | 0.82 | GRIK1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | claimed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-6407109-B1 | ANTIEPILETIC, ANTIDEPRESSANT, AND ANXIOLYTIC AGENTS; PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | GRIA1 2085/4885GRIA2 2341/4885GRIA3 2201/4885 |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIA1 22/4885GRIA2 21/4885GRIA3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.